MedinCell publishes its financial results and activity report for the first half of 2021-2022
December 8, 2021
December 8, 2021
Videoconference and publication of the 2021-2022 Half-Year Results, on December 8, 2021
December 2, 2021
December 2, 2021
MedinCell receives €4 million in funding from Bpifrance and within the framework of the French Recovery Plan (Plan France Relance)
December 1, 2021
December 1, 2021
Phase 3 data of mdc-IRM, first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia: – Prolonged time to impending relapse – Decreased risk of relapse – Increased chance of clinical stability
November 1, 2021
November 1, 2021
MedinCell announces participation in the Jefferies London Healthcare Conference 2021
October 25, 2021
October 25, 2021
MedinCell: mdc-IRM’s Phase 3 data to be presented for the first time by Teva at Psych Congress 2021
October 21, 2021
October 21, 2021
MedinCell releases the results of its September 9, 2021 ordinary annual and extraordinary general meeting
September 10, 2021
September 10, 2021
MedinCell provides an update on its product portfolio, following the FDA Acceptance of New Drug Application for the product mdc-IRM
September 1, 2021
September 1, 2021
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia
August 31, 2021
August 31, 2021
Participation terms in the MedinCell Combined General Meeting
